Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
February 17, 2026 Off

Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study

By BusinessWire

Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules…

February 17, 2026 Off

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

By BusinessWire

ATHENS, Greece & BELOIT, Wisc.–(BUSINESS WIRE)–BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research,…

February 17, 2026 Off

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

By BusinessWire

Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved…

February 17, 2026 Off

NationsBenefits and Kinney Drugs Partner to Expand Flex Card Access for Rx and OTC Health Needs in New York

By BusinessWire

PLANTATION, Fla.–(BUSINESS WIRE)–#NationsBenefits—NationsBenefits, the leading healthcare fintech and supplemental benefits platform, announced a new partnership with Kinney Drugs, a trusted,…

February 17, 2026 Off

Satellos to Participate in Upcoming Investor Conferences

By BusinessWire

TORONTO–(BUSINESS WIRE)–Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural…

February 17, 2026 Off

Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL

By BusinessWire

– Regulatory submission is based on positive results from the Phase 2 PROSPECT Study — – FDA sets PDUFA Date…

February 17, 2026 Off

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

By BusinessWire

SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today…

February 17, 2026 Off

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

By BusinessWire

Iberdomide has the potential to be the first approved CELMoD agent The U.S. FDA has granted Breakthrough Therapy Designation and…

February 17, 2026 Off

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

By BusinessWire

BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant metastatic colorectal…

February 17, 2026 Off

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

By BusinessWire

Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect…

Posts pagination

Previous 1 … 8 9 10 … 6,330 Next

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Precise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine